



## **Differential Response of Bradykinesia and Hypokinesia to** CleveMed Levodopa in Parkinson's Disease

<sup>1</sup>University of Cincinnati College of Medicine, Department of Neurology, Cincinnati, OH, USA, <sup>2</sup>Cleveland Medical Devices Inc., Cleveland, OH, USA, <sup>3</sup>University of Toronto, Department of Medicine, Division of Neurology, Toronto, Ontario, Canada

## Introduction

Although slowness (bradykinesia) and decreased amplitude (hypokinesia) of movements may be associated with differential impairment and disability in Parkinson's disease (PD), clinicians are asked to rate rapid alternating movements into a combined 0 – 4 severity scale through the Unified Parkinson's Disease Rating Scale motor subscale (UPDRS-III). Clinical raters consider multiple aspects of movement including speed, amplitude, hesitations, fatiguing, and arrests in movement. Previous research has shown that individual clinicians weigh individual components of bradykinesia differently, thus creating a considerable degree of variability across clinicians.

The objective of this study is to evaluate the motor function and response to dopaminergic drugs in patients with PD with various impairments in speed and amplitude of movement. Speed and amplitude are evaluated separately to determine if bradykinesia and hypokinesia should deserve separate clinical assessment.

## Methods

Eighty-five PD patients (Table 1) performed UPDRS-directed finger tapping, hand grasping, and pronation/supination tasks in the OFF (12-15 hours after dopaminergic drug withdrawal) and ON states while wearing wireless six-degree-of-freedom motion sensors (KinetiSense™, CleveMed) on the index finger and thumb (Figure 1). Each motion sensor contains three orthogonal accelerometers for measuring linear acceleration and three orthogonal gyroscopes for measuring angular velocity. A Modified Bradykinesia Rating Scale (MBRS) was used to assess separately speed and amplitude during the tasks on a 0 - 4 scale (Table 2). Quantitative variables representing speed (root-mean-square [RMS] angular velocity) and amplitude (RMS excursion angle) were extracted from kinematic data, correlated with clinical MBRS scores, and used to classify patients as hypokinetic, bradykinetic, both, or neither.

	Table 1. Patient Demographics			
Age (yr) (mean ± SD [range])			64.6 ±	
Gender			56 mer	
Disease Duration (yr) (mean ± SD [range])			9.5 ±	
UPDRS-III OFF (0-108; high: worse) (mean ± SD [range])			ange]) 25.7 ±	
UPDRS-III ON (0-108; high: worse) (mean ± SD [range])			nge]) 16.7 ±	
Hoehn and Yahr OFF (0-5; high: worse) (mean ± SD [range])			D [range]) 2.4 :	
Hoehn and Yahr ON (0-5; high: worse) (mean ± SD [range])			) [range]) 2.2 :	
		Einaar tang	<b>Pronation/S</b>	
-23		Finger taps	FIUNALIUN/J	
		Hand grasps	<b>Figure 1</b> . Motion sense finger and thumb re- while subjects perform grasping, and pronation	
		Table 2. Modified Bradyki	nesia Rating Scale <sup>1</sup>	
Score	Speed	Amplitude		
0	Normal	Normal		
1	Mild slowing	Mild reduction in amplitude in later perfor movements close to normal		
2	Moderate slowing	Moderate, reduction in amplitude visible e continues to maintain 50% amplitude thro		
3	Severe slowing	Severe, less than 50% amplitude through		
<b>_</b>				

Can barely perform the task Can barely perform the task <sup>1</sup>A. Kishore, A.J. Espay, C. Marras, T. Al-Khairalla, T. Arenovich, A. Asante, J. Miyasaki, and A.E. Lang, "Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia," Movement Disorders, vol. 22, 2007, pp. 328-333.

Alberto J. Espay<sup>1</sup>, Joseph P. Giuffrida<sup>2</sup>, Robert Chen<sup>3</sup>, Jennifer E. Vaughan<sup>1</sup>, Andrew P. Duker<sup>1</sup>, Dustin A. Heldman<sup>2</sup>

± 9.1 (46-85) n, 29 women ± 5.6 (2-31) 11.1 (4.5-66) : 9.9 (1-60.5) ± 0.6 (1-5) ± 0.5 (1-4)

Supination



sors placed on the index ecorded kinematic data med finger tapping, hand ion/supination tasks.

rmance, most

early in performance but ough most of the tasks h most of the task

# **Subgroup Classification**

RMS excursion angle and angular velocity were found to be highly correlated with clinician MBRS scores for amplitude and speed, respectively (Figure 2). These quantitative variables were used to classify subjects as bradykinetic only, hypokinetic only, both bradykinetic and hypokinetic, or neither bradykinetic nor hypokinetic. Subjects with average excursion angles worse than that corresponding to an average MBRS amplitude score of 1 were classified as hypokinetic, while subjects with average angular velocities worse than that corresponding to an average MBRS speed score of 1 were classified as bradykinetic.



Figure 2. Excursion angle (A) and angular velocity (B) are plotted versus clinician MBRS amplitude and speed scores, respectively. When summing scores across all tasks, excursion angle was highly correlated with amplitude scores (r = -0.67) and angular velocity was highly correlated with speed scores (r = -0.74).

## **Clinical Results**





While hypokinesia was more common and more pronounced than bradykinesia, our data suggest that dopaminergic drugs normalize bradykinesia more significantly than hypokinesia. Quantitative variables extracted from the kinematic data recorded using the motion sensors provided a high degree of sensitivity for examining separately speed and amplitude. Speed deficits were improved in all affected subgroups, while amplitude deficits were only significantly improved in subjects with speed deficits in addition to amplitude deficits. Speed and amplitude of movement are differentially associated with motor impairment in PD and deserve separate measurement in research studies.

## Acknowledgements

This work was supported by the Davis Phinney Foundation for Parkinson's disease and NIH/NINDS 2R44NS043816-04